Aurobindo Pharma Ltd. Share Price Today - Aurobindo Pharma Ltd. Stock Price Live NSE/BSE
NiveshIQ
NSE: AUROPHARMA · Healthcare
Aurobindo Pharma Ltd.
₹1,683.80▲ ₹2.40 (+0.14%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on AUROPHARMA. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Aurobindo Pharma Ltd.
Aurobindo Pharma Limited is a leading Indian generic pharmaceutical manufacturer with a diversified portfolio that includes oral solids, injectables, specialty branded drugs, and active pharmaceutical ingredients across therapeutic areas such as CNS, anti‑retroviral, cardiovascular, and oncology. In FY24, the company generated ₹34,935 crore in revenue and ₹3,713 crore in net income, reflecting a 12% YoY revenue growth driven by strong demand in the U.S. and European markets. Recent FDA actions—Unit‑IV receiving VAI status and Units VI and VII classified as OAI or voluntary action indicated—have bolstered the company’s regulatory compliance profile and expanded its U.S. commercial footprint. Aurobindo’s competitive edge stems from its high‑volume manufacturing capabilities, cost‑efficient s
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹29,002 Cr +16.68% | ₹31,724 Cr +9.39% | ₹33,653 Cr +6.08% |
| EBITDA Margin | 20.15% | 20.75% | 20.34% |
| Net Profit | ₹3,173 Cr +64.62% | ₹3,486 Cr +9.86% | ₹3,505 Cr +0.54% |
| EPS | ₹54.16 | ₹59.81 | ₹60.34 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Aurobindo Pharma (NSEI:AUROPHARMA) Stock Forecast & Analyst Predictions
How Much Headroom Does Aurobindo Pharma (NSE:AUROPHARMA) Have?
🔒
+ 3 more stories about Aurobindo Pharma Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹9, 150 Cr, PAT ₹1, 032 Cr, EPS ₹17.86, EBITDA margin 23.4%. Growth context: revenue QoQ +3.4%, PAT QoQ +12.1%. Street verdict: inline, revenue surprise +1.6%, PAT surprise +3.9%.
Management highlights geographic expansion and international growth as the key near‑term growth lever, with execution on...
FY26 (last completed FY): revenue ₹33, 653 Cr, PAT ₹3, 567 Cr, EBITDA margin 21.8%, EPS ₹60.34. Year-on-year: revenue Yo...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for AUROPHARMA
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track AUROPHARMA alongside your other holdings
Unlock full AUROPHARMA research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Aurobindo Pharma Ltd.?
NiveshIQ detects active intelligence signals for Aurobindo Pharma Ltd. (AUROPHARMA) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Aurobindo Pharma Ltd.?
Aurobindo Pharma Ltd. operates in the Healthcare sector with a market capitalisation of ₹8,625,484.6L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.